2. Signaling Pathways
  3. Anti-infection
  4. HBV

HBV

Hepatitis B virus

HBV

Related Products

PDF 0.42 MB

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-120377
    CYP1A1 inhibitor 8a
    		Inhibitor
    CYP1A1 inhibitor 8a is a compound that potently and selectively inhibits the CYP1A1 enzyme and has the potential to prevent cancer. CYP1A1 inhibitor 8a exhibits more than 10-fold selectivity for CYP1A1 and more than 100-fold selectivity over other enzymes in the CYP1 subfamily. CYP1A1 inhibitor 8a can effectively antagonize B[a]P-mediated activation of the aryl hydrocarbon receptor (AhR) in yeast cells and protect human cells from CYP1A1-mediated B[a]P toxicity. CYP1A1 inhibitor 8a has the potential to be developed as a cancer chemopreventive agent.
    CYP1A1 inhibitor 8a
  • HY-158329
    Alloc-DOX
    		Inhibitor
    Alloc-DOX (N-Alloc doxorubicin) is a Doxorubicin (HY-15142A) prodrug. The combination of a catalyst (such as nano-palladium) and alloc-DOX leads to a decrease in cell viability and tumour growth.
    Alloc-DOX
  • HY-B0250S1
    Lamivudine-13C,15N2,d2
    		Inhibitor
    Lamivudine-13C,15N2,d2 (BCH-189-13C,15N2,d2) is a 13C, 15N, and deuterium labeled Lamivudine (HY-B0250). Lamivudine is an orally active and blood-brain barrier permeable nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine inhibits HIV reverse transcriptase 1 and 2 and hepatitis B virus (HBV) reverse transcriptase.
    Lamivudine-<sup>13</sup>C,<sup>15</sup>N<sub>2</sub>,d<sub>2</sub>
  • HY-145049
    HBV-IN-6
    		Inhibitor
    HBV-IN-6 is a potent HBV inhibitor with an EC50 of 44 nM (WO2021213445A1, compound 3).
    HBV-IN-6
  • HY-P4045
    HBV Seq2 aa:208-216
    HBV Seq2 aa:208-216, a HBsAg derived CD8 epitope peptide, is studied as part of Large envelope protein from Hepatitis B virus.
    HBV Seq2 aa:208-216
  • HY-149468
    Antiviral agent 38
    		Inhibitor
    Antiviral agent 38 (compound 2.1-1) is a potent antiviral agent. Antiviral agent 38 can be used for hepatitis B virus (HBV) research.
    Antiviral agent 38
  • HY-156702
    HBV-IN-38
    		Inhibitor
    HBV-IN-38 (Example 193) is an HBV DNA inhibitor (EC50≤100nM). HBV-IN-38 can be used to study viral infections.
    HBV-IN-38
  • HY-161605
    HBV/HDV-IN-2
    		Inhibitor
    HBV/HDV-IN-2 (Compd 143) is a HBV, HDV and PD-1/PD-L1 inhibitor, with an EC50 of 35 nM for T cell activation.
    HBV/HDV-IN-2
  • HY-121850
    Rolicyprine
    		Inhibitor
    Rolicyprine (EX-4883) is an antidepressant with neuroprotective activity. Rolicyprine can improve depressive symptoms and promote neuroregeneration. Rolicyprine also shows potential effectiveness for anxiety suppression.
    Rolicyprine
  • HY-162795
    HBV-IN-47
    		Inhibitor
    HBV-IN-47 (compound 4a) is a capsid assembly regulator with inhibitory activity against hepatitis B virus (HBV). HBV-IN-47 exhibits strong anti-HBV activity in HepAD38 cells with low toxicity (EC50=0.24 μM). HBV-IN-47 can be used for the study of chronic hepatitis B (CHB).
    HBV-IN-47
  • HY-N3861
    Erythrocentaurin
    		Inhibitor
    Erythrocentaurin, a natural compound, is a new class of hepatitis B virus inhibitor.
    Erythrocentaurin
  • HY-129923R
    (R)-Omeprazole (sodium) (Standard)
    		Inhibitor
    (R)-Omeprazole (sodium) (Standard) is the analytical standard of (R)-Omeprazole (sodium). This product is intended for research and analytical applications. (R)-Omeprazole sodium is a gastric acid resistant compound with activity to inhibit gastric acid secretion. (R)-Omeprazole sodium is metabolized in vivo, and its metabolism is primarily affected by cytochrome P450 enzymes. The interaction between (R)-Omeprazole sodium and mannitol may affect its bioavailability in formulations. (R)-Omeprazole sodium exhibits reversible direct and metabolism-dependent inhibition of CYP2C19.
    (R)-Omeprazole (sodium) (Standard)
  • HY-B0250S
    Lamivudine-15N,d2
    		Inhibitor
    Lamivudine-15N,d2 is 15N and deuterated labeled Lamivudine (HY-B0250). Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS.
    Lamivudine-<sup>15</sup>N,d<sub>2</sub>
  • HY-169993
    ALG-000184
    		Inhibitor
    ALG-000184, a prodrug of the potent Hhepatitis B virus (HBV) capsid assembly modulator ALG-001075, has the potential for the research of HBV infection research.
    ALG-000184
  • HY-148172
    L-Fd4A
    		Inhibitor
    L-Fd4A is an adenine derivative. L-Fd4A has anti-human immunodeficiency virus (HIV) (EC50=1.5 μM) and anti-hepatitis B virus (HBV) (EC50=1.7 μM) activity. L-Fd4A has low cytotoxicity.
    L-Fd4A
  • HY-W352344
    2'-Deoxy-L-adenosine
    		Inhibitor
    2'-Deoxy-L-adenosine is an orally active synthon for modified oligodeoxyribonucleotides. 2'-Deoxy-L-adenosine is a potent, specific and selective inhibitor of the replication of hepatitis B virus (HBV) as well as the closely related duck and woodchuck hepatitis viruses (WHV).
    2'-Deoxy-L-adenosine
  • HY-P4043
    Hepatitis b virus pre-s region (120-145)
    		Inhibitor
    Hepatitis b virus pre-s region (120-145) is a preS2 peptide that inhibits the binding of single-chain Fv fragment (scFv) or IgG to r-HBsAg.
    Hepatitis b virus pre-s region (120-145)
  • HY-156665
    HBV-IN-37
    		99.04%
    HBV-IN-37 is an inhibitor of HBV with an EC50 value of 10 μM.
    HBV-IN-37
  • HY-170605
    BA-AZT1
    		Inhibitor
    BA-AZT1 is the inhibitor for HBV polymerase and sodium taurocholate cotransporting polypeptide (NTCP). BA-AZT1 inhibits the secretion of viral capsid protein HBsAg and HBeAg with IC50 of 0.65 µM and 13.42 µM, inhibits the HBV DNA replication with an IC50 of 0.70 µM.
    BA-AZT1
  • HY-149357
    Yhhu6669
    		Inhibitor
    Yhhu6669 is an anti-HBV agent. Yhhu6669 inhibits HBV DNA. Yhhu6669 inhibits HBV replication by inducing the formation of DNA-free capsids. Yhhu6669 decreases HBV DNA and HBcAg in AAV/HBV-infected mice. Yhhu6669 has favorable PK properties.
    Yhhu6669
Cat. No. Product Name / Synonyms Application Reactivity